SOB100 is the first proprietary platform “HLA-G targeted exosome” successfully developed by ShineOn, poised for scalable industrial production in novel drug development. The design of SOB100 received positive feedback from FDA. HLA-G serves not only as an immune checkpoint but also as a neo tumor target, highly overexpressed on various tumor cells. Exosomes engineered with HLA-G-specific nanoantibodies precisely navigate exosome to tumor cells expressing HLA-G.
Among the 3 exosomal pipeline products under development by ShineOn, SOB101 and SOB102 are SOB100-derived exosomal drugs.
![](/upload/images/%E6%A8%99%E9%9D%B6%E5%A4%96%E6%B3%8C%E9%AB%94%E6%8A%80%E8%A1%93%E5%B9%B3%E5%8F%B0(1).jpg)